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Inherited cardiovascular (CV) conditions are common, and comprehensive care of affected 
families often involves genetic testing. When the clinical presentations of these conditions 
overlap, genetic testing may clarify diagnoses, etiologies, and treatments in symptomatic 
individuals and facilitate the identification of asymptomatic, at-risk relatives, allowing
for often life-saving preventative care. Although some professional society guidelines
on inherited cardiac conditions include genetic testing recommendations, they quickly 
become outdated owing to the rapid expansion and use of such testing. Currently, these 
guidelines primarily discuss the benefits of targeted genetic testing for identifying at-risk 
relatives. Although most insurance policies acknowledge the benefit and the necessity of 
this testing, many exclude coverage for testing altogether or are vague about coverage 
for testing in probands, which is imperative if clinicians are to have the best chance of 
accurately identifying pathogenic variant(s) in a family. In response to uncertainties about 
coverage, many commercial CV genetic testing laboratories have shouldered the burden 
of working directly with commercial payers and protecting patients/institutions from out-
of-pocket costs. As a result, many clinicians are unaware that payer coverage policies 
may not match professional recommendations for CV genetic testing. This conundrum 
has left patients, clinicians, payers, and laboratories at an impasse when determining the 
best path forward for meaningful and sustainable testing. Herein, we discuss the need 
for all involved parties to recognize their common goals in this process, which should 
motivate collaboration in changing existing frameworks and creating more sustainable 
access to genetic information for families with inherited CV conditions.
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cascade testing
iNtrODUctiON
Inherited cardiovascular (CV) conditions include arrhythmias, cardiomyopathies, aortopathies, and 
dyslipidemias. These conditions affect more than 1 in 200 individuals, and several of them have 
considerable phenotypic overlap. Therefore, comprehensive care of affected patients and families 
often involves multi-gene panel-based genetic testing, which can clarify diagnoses and etiologies. 
Since becoming available in the early to mid-2000s, panel-based CV genetic tests have seen widening 
clinical adoption. The range of conditions covered by current commercial CV genetic testing and the 
number of genes included in analyses have also expanded exponentially.
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Advances in CV diagnostics have spurred changes for insur-
ance companies, genetic testing laboratories, and professional 
cardiology societies, which have created coverage policies, devel-
oped expanded panel-based tests, and formulated care guidelines, 
respectively. However, the question of who pays for CV genetic 
testing is ongoing and relates to both the applicability of genetic 
testing in probands and at-risk relatives and the need for sustain-
ability in laboratory services and payer policies.
Herein, we review the current status of genetic testing guidelines 
for inherited CV conditions and the roles of payers and genetic test-
ing laboratories in providing access to testing for affected families. 
We also discuss the inconsistencies among clinical approaches, 
professional society guidelines, payer policies, and laboratory 
practices that have influenced this access. Finally, we highlight the 
shared goals of all stakeholders and discuss how these overlapping 
interests are a starting point on the path to sustainable, accessible 
genetic testing for patients with inherited CV conditions.
HistOrY OF cv GeNetic testiNG
Although genotype–phenotype correlations remain in their 
infancy in CV genetics, genetic test results can have key impacts 
on patient care and management by clarifying clinical presentation 
and etiology, aiding decision-making about surgical procedures, 
and guiding medication selection and surveillance strategies. For 
example, long QT syndrome subtyping (for types 1, 2, and 3) 
provides some indication of both responsiveness to certain treat-
ments and the presence of higher-risk situations that may trigger 
cardiac events. In cardiac hypertrophy, genetic testing can identify 
underlying causal conditions (e.g., Fabry disease, Danon disease, 
Pompe disease, transthyretin amyloidosis). Alfares et al. (1) found 
that 3% of hypertrophic cardiomyopathy (HCM) patients who 
underwent genetic testing had an undetected syndromic disease 
that presented an opportunity for more effective treatment (e.g., 
enzyme replacement therapy in Fabry disease). Earlier clarification 
of cardiomyopathy etiology through genetic testing in children, in 
which metabolic causes are much more frequent, can also improve 
treatment outcomes. When cardiomyopathies are associated with 
conduction disease or higher arrhythmogenic potential, the 
increased likelihood of changes in certain genes (e.g., SCN5A, 
LMNA) warrant closer surveillance and specific intervention from 
a cardiac electrophysiologist and a heart failure/cardiomyopathy 
specialist (2). Moreover, in the case of overlapping aortopathies 
(Marfan syndrome versus Loeys–Dietz syndrome), genetic test 
results can guide the timing of surgical intervention, which differs 
based on the etiology of aortic disease (3). The risks for recur-
ring aortic aneurysms/dissection, the most vulnerable portions 
of the aorta, and the involvement of additional vasculature also 
vary according to etiology; therefore, genetic testing can guide the 
choice of imaging method and frequency of ongoing surveillance.
Until recently, long turnaround times  –  typically 
8–12 weeks – could be expected for CV genetic tests. Therefore, 
the results have generally been less routinely useful for planning 
immediate patient care. Furthermore, CV genetic test results may 
not have direct management implications for the individual tested. 
Often, the primary benefit of CV genetic testing comes in uncov-
ering pathogenic variants in probands that can then be used for 
targeted genetic testing to identify at-risk family members (cascade 
screening) and plan their surveillance and, equally important, 
reduce risk in family members to the population baseline when 
they test negative for variants. Early diagnosis of hereditary CV 
conditions improves outcomes; therefore, early identification of 
at-risk family members improves outcomes as well.
Historically, CV genetic testing has been covered only spo-
radically by insurance and has been cost prohibitive for patients. 
The ability to direct family cardiac screening is valuable for both 
patients and payers, but this reason alone is not always a convinc-
ing argument for why payers should cover testing for probands. 
For example, Medicare specifically prohibits the genetic testing of 
both affected patients and asymptomatic at-risk family members, 
if the test will benefit individuals other than Medicare patients 
themselves.
PrOFessiONAL GUiDeLiNes FOr cv 
GeNetic testiNG
Practice guidelines drafted by professional cardiology and 
genetics societies aim to provide patient care recommendations 
(evidence-based, when possible) that lead to the best clinical 
outcomes. The guidelines for the inherited arrhythmias and 
cardiomyopathies currently address genetic testing most thor-
oughly. These guidelines were published in 2009 by the Heart 
Failure Society of America (4) and in 2011 by the American 
College of Cardiology Foundation/American Heart Association 
(ACCF/AHA) (5) and the Heart Rhythm Society/European Heart 
Rhythm Association (HRS/EHRA) (2).
Genetic testing is a class I recommendation (“is recom-
mended”) in probands for just 5 of the 13 conditions covered in the 
HRS/EHRA document, including individuals with strong clinical 
suspicion of long QT syndrome, catecholaminergic polymorphic 
ventricular tachycardia, HCM, and dilated cardiomyopathy in the 
presence of conduction disease or a family history of premature 
unexpected death, as well as individuals who have survived an 
out-of-hospital cardiac arrest when a specific channelopathy 
or cardiomyopathy is suspected. However, cascade testing for a 
pathogenic variant, previously identified in a family proband, is a 
class I recommendation for all but 1 of the 13 conditions included.
The available professional guidelines are sometimes inconsist-
ent. For example, unlike the HRS/EHRA statement described 
above, the ACCF/AHA guidelines for HCM recommend genetic 
testing only for probands with atypical presentations that raise 
suspicion of an underlying syndromic etiology. For all other 
individuals with HCM, the guidelines classify genetic testing as a 
class II recommendation (“is reasonable”), specifically to facilitate 
the identification of at-risk family members (5).
Unlike the National Comprehensive Cancer Network 
guidelines for oncology, which are updated annually to provide 
recommendations for genetic testing, the guidelines provided 
by professional societies in CV medicine are updated too infre-
quently to serve as comprehensive recommendations for patient 
management. In addition, the National Comprehensive Cancer 
Network guidelines are highly specific about the genes to test and 
how the results of testing will influence management and sur-
veillance of the proband undergoing testing. A lack of available 
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clinical data on the use of genetic testing to improve long-term 
outcomes in patients with inherited CV conditions means that 
much of the professional guidance for cardiac genetic testing is 
based on expert opinion and experience rather than accumulated 
evidence. As such, the NCCN guidelines are closely followed by 
many major payers, unlike the current cardiology recommenda-
tions, which are rarely consistent with insurance coverage policies 
and may be considered insufficient by payers for determining 
which tests and which individuals to cover in affected families.
The American College of Medical Genetics and Genomics has 
published a “must-report” guideline related to clinically useful 
pathogenic test results of whole-exome or whole-genome analysis 
(6). The guideline specifies 56 genes for which findings are impor-
tant for all patients to know and should be conveyed by clinicians 
even if they are secondary to a patient’s original indication for 
genetic analysis. This guideline underscores the value of genetic 
information for clinicians engaged in patient care and their desire 
to use genetic test results to guide the care they provide. Thirty-
one of these genes are related to cardiac conditions; however, 
commercial payers do not cover genetic testing for some of these 
genes, even in probands suspected of having the condition.
PAYer POLicies
Payer policies are driven by the goal of providing quality health 
care to all clients in a sustainable, cost-effective way. The down-
stream cost savings of initiating appropriate genetic testing in 
a family proband with cardiomyopathy followed by targeted 
genetic testing in related family members are considerable (1, 
7, 8). These savings occur when relatives who did not inherit a 
known familial pathogenic variant can be released from further 
cardiac surveillance, and the testing and intervention recommen-
dations for at-risk family members can be refined and optimized. 
However, evidence of these cost savings has not yet translated to 
wider payer coverage for genetic testing in probands.
Coverage policies for CV genetic testing are inconsistent 
among payers. When policies do include panel testing, different 
payers sometimes cover testing for different genes for the same 
condition. Because professional guidelines do not offer up-to-
date, gene-specific, evidence-based guidance, it is unclear who is 
selecting the genes to be covered and what information is guiding 
or informing the selections.
For clinicians and families, these inconsistencies impede effi-
cient decision-making and delivery of care. Written policies on 
medical necessity for specific CV conditions are often unavailable, 
which means that clinicians and patients have no assurance that 
genetic testing will be authorized or covered. This lack of specific 
documentation exists even for Medicare/Medicaid policies, in 
which coverage details for non-oncology genetic testing rarely 
exist and, when present, are tied to medical necessity. Medical 
necessity often remains undetermined by payers until a claim is 
submitted, and the expectations of patients and clinicians about 
the medical necessity of testing often differ significantly from the 
definitions adhered to by payers.
Even when CV genetic testing is covered, clinical decisions are 
further complicated by the extent of coverage provided. In many 
cases, payers cover only testing deemed medically necessary for 
the individual covered. Familial probands must undergo genetic 
testing to determine the underlying genetic cause of an inherited 
CV condition before cascade testing can begin. Until then, at-risk 
family members whose genetic testing is medically necessary and 
covered by insurance cannot obtain authorization for testing. 
Coverage denials based on medical necessity in probands create 
obstacles for both determining the underlying genetic cause of 
a familial CV condition and allowing at-risk family members 
to take advantage of genetic testing that is covered under their 
policies. Coverage/no-coverage combinations within affected 
families can become ongoing catch-22s in the management of 
life-threatening health conditions.
To the best of our knowledge, only one policy, from the com-
mercial payer Aetna (9), successfully navigates the murky waters 
of proband/at-risk relative coverage for genetic testing. This 
policy states that the payer will cover oncologic genetic testing 
for a non-member familial proband whose own insurance has 
denied coverage, if the results are needed to pursue the medically 
necessary targeted testing of a covered at-risk family member. 
How often this coverage clause is used or honored, and what 
mechanism the payer has established to extend such coverage are 
unknown, but this example may be a model for consideration 
in CV genetics, in particular, because the primary benefit of most 
CV genetic tests is the identification of at-risk relatives.
cOMMerciAL LABOrAtOrY BiLLiNG 
POLicies
Genetic testing laboratories aim to provide quality, maximally 
accessible genetic testing to patients and clinicians. Costs and 
payment processes for genetic testing are generally dictated by 
the method in which tests are ordered and billed. Institutional 
billing, in which an institution (hospital) pays the laboratory 
performing the test and then bills and collects the payment from 
both the patient’s insurance and the patient, is the only option 
for some clinicians. Other institutions do not allow clinicians to 
use institutional billing, and instead, require them to work with 
laboratories that can bill payers directly.
Laboratories that cannot bill insurers directly may require that 
all orders be handled by an institutional billing process at the 
clinician’s facility. To cover the costs associated with billing and 
collecting from both patients and payers, institutions in so-called 
mark-up states may charge more for testing. Figure 1 demonstrates 
the complexity of current billing processes for genetic testing.
Many commercial laboratories that bill patient insurance 
companies directly also devote customer service resources to 
payment planning or cost reductions for qualifying patients who 
sometimes bear significant out-of-pocket costs despite having 
insurance coverage. However, these additional services may be 
unavailable to patients with non-commercial insurance and are 
advantageous only to clinicians who can send samples directly to 
testing laboratories.
Cost often emerges as a key factor for patients in deciding 
whether to pursue testing recommended by their clinicians. 
Having laboratories take responsibility for billing and coverage/
cost determination has increased both patient access and clinician 
FiGUre 1 | Billing and payment pathways for genetic testing. *Pretest insurance work includes benefits investigation, pre-certification, prior authorization, and 
discussion of costs with patients.
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utilization of CV genetic testing but has not necessarily improved 
insurance coverage for these tests. Furthermore, taking these 
processes out of the hands of clinicians has created a situation 
in which genetic testing stakeholders do not always realize that 
treatment decisions, professional guideline recommendations, 
and payer coverage policies are misaligned.
cHALLeNGes iN tHe cv cLiNic
The disconnect between practice guidelines and coverage poli-
cies presents barriers to the timely and effective provision of care 
to patients with inherited CV disorders. Patient confusion can 
arise when testing that clinicians call “recommended” is consid-
ered “experimental” or “investigational” by payers. With vastly 
different payer policies or no clear policy to rely on, clinicians 
have difficultly determining whether patients can proceed with 
genetic testing and, if so, when testing can take place and what 
out-of-pocket expenses will be incurred (e.g., which tests are 
covered and which are not and which billing process – the insti-
tution’s or the laboratory’s – will yield the lowest out-of-pocket 
expense). The time required to find answers to these questions 
could be better spent counseling patients, and the delays in 
testing that occur while insurance policies are being clarified 
FiGUre 2 | shared goals of clinicians, payers, genetic testing 
laboratories, and professional cardiology and genetics societies are 
starting points for the development of sustainable genetic testing 
practices for patients with inherited cardiovascular conditions.
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can create added concern for patients facing potentially serious 
diagnoses.
Furthermore, clinicians are inadequately trained to advise 
patients about the implications of various billing policies, and their 
lack of expertise may introduce legal liabilities. Few clinicians can 
differentiate among a pre-verification, a pre-determination, and 
a pre-authorization, for example, and even if they can, obtaining 
these clearances from payers often does not guarantee coverage. 
Discussions about expense are appropriate and necessary in deci-
sions about patient care and management. However, compared 
with other routinely ordered medical tests (e.g., echocardiogram, 
electrocardiogram, magnetic resonance imaging) in cardiology 
clinics, orders for genetic testing frequently require clinicians 
to take a more prominent financial/insurance counseling role 
because uncertainties about coverage put cost at the center of 
diagnosis and treatment decisions.
In some cases, clinicians may alter the genetic testing strategy 
in a family based on the type of insurance coverage available for 
the required test – for example, selecting a different relative with 
a better insurance situation for testing. Gathering and assessing 
all of the necessary documentation to make decisions about 
testing logistics has the potential to be a complicated process 
that prevents some patients from receiving recommended and 
appropriate CV genetic testing in a timely manner.
PAtH FOrWArD
Genetic testing in the management of inherited CV conditions 
is here to stay. Its utility in the care of families with inherited 
CV conditions has been established, and genotype–phenotype 
correlations will likely become more refined as sequencing 
technologies advance. Therefore, the establishment of clear 
professional guidelines and consistent payer policies is crucial if 
affected families are to benefit from the availability of accurate 
and effective testing. To make recommendations and coverage 
work hand in hand, payers, laboratories, clinicians, and profes-
sional CV and genetics societies must collaborate and recognize 
their shared goals in caring for these patients (Figure 2).
Because all stakeholders agree that cascade testing can improve 
outcomes through early identification of individuals at risk for 
inherited CV conditions, the key issues are primarily those about 
coverage and billing. Should a family member’s insurance policy 
pay for CV genetic testing in a proband in some scenarios, as 
exemplified by the Aetna policy described above? If so, insurers 
must collectively determine what policy clauses or mechanisms 
are required to ensure that patients can benefit regardless of the 
coverage combinations within their families. Input from profes-
sional organizations – perhaps through more frequent updating of 
published CV genetic testing practice guidelines – is likely to help 
in standardizing the types of tests clinicians order and payers cover.
In the meantime, if billing continues to be handled by labora-
tories, clinicians should collect data about which tests are being 
covered and denied to improve responsible ordering practices. 
Many clinicians prefer laboratory billing because it saves time, and 
owing to laboratory-based customer service resources, this path 
often provides assurance that patients will not see unexpected bills. 
However, if this billing arrangement is not ensuring coverage and 
hides gaps in coverage, it will neither provide sustainable patient 
access to testing nor help clinicians advocate for changes in payer 
policies. Clinicians must recognize opportunities for engaging 
with the billing process and educating payers and guideline writers 
on the need for and applications of CV genetic testing.
From a health economics standpoint, available data suggest 
that genetic testing can provide cost savings (1, 7, 8). However, 
additional data are needed to demonstrate its cost-effectiveness. 
Also needed are specific, up-to-date practice guidelines backed by 
appropriate cardiology and genetics societies (e.g., HRS, ACCF, 
AHA, National Society of Genetic Counselors, American College 
of Medical Genetics and Genomics) to encourage appropriate 
guideline implementation and reduce misdirected use of genetic 
testing, which drives up health-care costs for payers without 
benefiting patients and families. These could be frequently 
re-evaluated, making any necessary updates or changes, akin 
to the process followed by the National Comprehensive Cancer 
Network for the Clinical Practice Guidelines in Oncology 
regarding Genetic/Familial High-Risk Assessment. Discussions 
between clinicians and payers about coverage will be critical as 
the costs of genetic testing decrease.
The current landscape of CV genetic testing is complex and 
involves stakeholders with different purposes, constraints, and 
scopes of care. No single entity can resolve the current challenges 
alone, and all parties must understand each other’s points of view 
and recognize opportunities for clearing the path toward more 
effective and accessible genetic testing coverage. For example, cli-
nicians are well positioned to partner with payers to help conduct 
necessary research about the clinical utility of currently available 
CV genetic testing and cost-effectiveness of cascade screening, 
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and professional societies are uniquely positioned to update 
and maintain consensus testing guidelines that can inform both 
clinicians and payers. Only through such collective understand-
ing and discussion will processes and policies emerge that both 
safeguard clinician and patient access to testing and guarantee 
sustainability for laboratories and payers.
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